Premenopausal Osteoporosis: How to Treat?

Martínez-Morillo, Melania; Grados, Dolors; Holgado, Susana

doi:10.1016/j.reumae.2011.05.005

Cited by 10 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This could be explained by the slight rise of some pro-inflammatory cytokines in perimenopause, in our case IL-1β. Recent studies have shown that about 50% of premenopausal women that present low BMD values and osteoporosis have an idiopathic cause (33). This could also be the case in our study, patients being excluded for secondary causes.…”

Section: Discussionsupporting

confidence: 57%

Bone Mineral Density and Proinflamatory Cytokines (IL-1ß and TNFa) in Menopause

Măluţan¹

2014

Acta Endo (Buc)

View full text Add to dashboard Cite

Background. Osteoporosis has a high incidence after menopause, and at the same time the relationship between menopausal oestrogen deprivation and proinflammatory status is considered to be involved in postmenopausal bone turnover.Objective. The aim of this study was to evaluate the serum levels of IL-1β and of the TNFα in pre and postmenopausal women, as well as to investigate the relationship between these cytokines and bone mineral density.Design. A case-control study was performed during a period of 12 months.Subjects and Methods. The study included 150 women divided into 4 study groups. Serum levels of IL-1β and TNFα were determined using multiplex cytokine kits. BMD was measured by DXA at the level of the hip and lumbar spine.Results. Serum concentration of IL-1β is significantly higher in natural and surgically induced menopausal women, compared to women in the control group. Serum levels of TNFα in postmenopausal women and with surgically induced menopause are significantly higher than in fertile and premenopausal women. Serum levels of IL-1β are significantly higher in patients with osteopenia and osteoporosis compared to patients with normal BMD values. We found a negative correlation between serum levels of IL-1β, TNFα and BMD in pre and postmenopausal women, and in women with surgically induced menopause.Conclusions. Serum levels of IL-1β and TNFα are significantly higher in menopausal women compared to fertile women. IL-1β is significantly higher in patients with osteopenia and osteoporosis than in women with normal BMD values, and IL-1β and TNFα associate negatively with BMD in pre and postmenopausal women, as well as in women with surgically induced menopause.

show abstract

Section: Discussionsupporting

confidence: 57%

Bone Mineral Density and Proinflamatory Cytokines (IL-1ß and TNFa) in Menopause

Măluţan¹

2014

Acta Endo (Buc)

View full text Add to dashboard Cite

show abstract

“…Premenopausal women referred to a bone disease referral program at a tertiary medical center were evaluated for secondary versus idiopathic osteoporosis [10]. A retrospective review of all Osteoporosis in younger women results from either a low peak bone mass, increased bone loss prior to menopause or both [1]. Peak bone mass is reached by 30 years of age with 90% of the development completed by 18 years of age [2].…”

mentioning

confidence: 99%

A Review of Osteoporosis Management in Younger Premenopausal Women

McLendon

Woodis

2014

Womens Health (Lond Engl)

View full text Add to dashboard Cite

The purpose of this review is to describe the available evidence for osteoporosis treatments in young and premenopausal women. A review of articles evaluating the treatment or prevention of osteoporosis in young (age less than 50 years) or premenopausal women was conducted. Several trials evaluating the treatment of anorexia nervosa and use of hormone therapy in those women, the use of bisphosphonates in women undergoing chemotherapy for breast cancer and the use of bisphosphonates, teriparatide and vitamin D in women with glucocorticoid-induced osteoporosis are described. Limited data were found to support the treatment of osteoporosis in women with idiopathic osteoporosis or cystic fibrosis, or after kidney transplant. The evidence for treatment of osteoporosis in premenopausal women is not nearly as robust as that for postmenopausal osteoporosis. Although fracture risk in the premenopausal population is low, women with secondary osteoporosis may benefit from treatment with various agents, depending upon the condition.

show abstract

“…In Type 1 osteoporosis, cortical bone was less affected than trabecular bone, leading to fractures in regions high in trabecular bone content, the spine and distal forearm [11] . Secondary osteoporosis is associated with a known triggering disease or medications [12] that listed in Table 1.…”

Section: A Review On Glucocorticoids Induced Osteoporosis: Pathogenesmentioning

confidence: 99%

A Review on Glucocorticoids Induced Osteoporosis: Pathogenesis, Diagnosis and Management by Some Natural Plants

Khaliefa¹,

El-Desouky²,

Hozayen³

et al. 2016

IJFNS

View full text Add to dashboard Cite

200 million person all over the world affected by osteoporosis as it is most common metabolic bone disorder. The general reason of bone loss are age and menopause, and the rates of bone loss variable between individuals. Physical activity and environmental factors as nutrition can contribute to bone health as they modify both peak bone mass and following bone loss. Medications embrace both antiresorptive and anabolic types. Antiresorptive medications acts by reducing rates of bone remodeling like estrogens, selective estrogen receptor modulators (raloxifene), bisphosphonates (alendronate, risedronate, and ibandronate) and calcitonins. Parathyroid hormone is the only anabolic medication. The nonmedical treatment must be used with pharmacologic treatment to maximize outcomes for osteoporotic patient. Some plant-derived natural products, mostly phytoestrogens (isoflavones, lignans, coumestanes, stilbenes) and many more novel estrogen-like compounds in plants have been greatly used to prevent depletion in bone mineral density. In this review an attempt has been made out to compile the mechanisms of glucocorticoids induced osteoporosis, the medicinal plants which are commonly utilized in osteoporosis with their prominent chemical ingredients and certain pharmacological actions.

show abstract

Premenopausal Osteoporosis: How to Treat?

Cited by 10 publications

References 38 publications

Bone Mineral Density and Proinflamatory Cytokines (IL-1ß and TNFa) in Menopause

Bone Mineral Density and Proinflamatory Cytokines (IL-1ß and TNFa) in Menopause

A Review of Osteoporosis Management in Younger Premenopausal Women

A Review on Glucocorticoids Induced Osteoporosis: Pathogenesis, Diagnosis and Management by Some Natural Plants

Contact Info

Product

Resources

About